Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
Mark T. Drayson(University of Birmingham), Janet Dunn(National Health Service), Claire Hulme(University of Leeds), Kamaraj Karunanithi(University Hospitals of North Midlands NHS Trust), Irene M. Monahan(St George's, University of London), Peter M. Hawkey, Beth Harrison(Brigham and Women's Hospital), Gavin Campbell(East Suffolk and North Essex NHS Foundation Trust), Kerry Raynes(University of Warwick), Bryony Dawkins(University of Leeds), Edward Belsham(Portsmouth Hospitals NHS Trust), Helen Higgins(University of Warwick), Helen Dignum(Portsmouth Hospitals NHS Trust), Guy Pratt(Heart of England NHS Foundation Trust), Anand Lokare(University Hospitals Coventry and Warwickshire NHS Trust), Kwee Yong(London Cancer), Gulnaz Iqbal(University of Warwick), David Meads(University of Leeds), Stella Bowcock(King's College Hospital), Eric Low(RED Consulting (Norway)), Jill Wood(University of Warwick), Anna C. Phillips(University of Birmingham), Michael R. Hamblin(Harvard University), Jeff Neilson(Russells Hall Hospital), Tim Planche(Leeds Teaching Hospitals NHS Trust)
Cited by 160
Related Papers
Photodynamic therapy of cancer: An update
|CA A Cancer Journal for Clinicians|2011|5.1k
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Antimicrobial strategies centered around reactive oxygen species – bactericidal antibiotics, photodynamic therapy, and beyond
|FEMS Microbiology Reviews|2013|1.1k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Cell Death Pathways in Photodynamic Therapy of Cancer
|Cancers|2011|675